Eicos Sciences, Inc.
🇺🇸United States
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)
Phase 3
Completed
- Conditions
- Raynaud's Phenomenon Secondary to Systemic Sclerosis
- Interventions
- Drug: Placebo IV infusion
- First Posted Date
- 2019-07-31
- Last Posted Date
- 2021-07-14
- Lead Sponsor
- Eicos Sciences, Inc.
- Target Recruit Count
- 198
- Registration Number
- NCT04040322
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸University of California, Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸Arizona Arthritis & Rheumatology Research, PLLC, Phoenix, Arizona, United States
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)
Phase 2
Completed
- Conditions
- Raynaud Phenomenon Secondary to Systemic Sclerosis
- Interventions
- Drug: Placebo IV infusion
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Eicos Sciences, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT03867097
- Locations
- 🇺🇸
University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics, Houston, Texas, United States
🇺🇸Hospital for Special Surgery, New York, New York, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath